OBJECTIVE To provide reference for the safety and effectiveness of antithrombotic therapy in patients with systemic lupus erythematosus complicated by acute cerebral infarction with hemorrhagic transformation.

METHODS Clinical pharmacists participated in analyzing the antithrombotic treatment for an systemic lupus erythematosus patient with hemorrhagic transformation following acute cerebral infarction. This included evaluating the impact of the underlying disease on coagulation function, assessing the risks of cerebral infarction recurrence and bleeding, formulating drug selection strategies for antithrombotic therapy, and developing an individualized treatment plan.

RESULTS Following the clinical pharmacist’s recommendation, antiplatelet therapy was resumed 15 days after the hemorrhage, with no bleeding events occurring.

CONCLUSION Clinical pharmacists should actively fulfill their roles in clinical practice, collaborate closely with physicians, and jointly promote rational drug use to enhance therapeutic outcomes.